drugset / Trial / NCT06746831
Methamphetamine Isomer Pharmacology in Humans
Phase 1
Not yet recruiting
17 enrolled
University of Wisconsin, Madison
U.S. Department of Justice · collab
RandomizedCrossoverDouble-blindTreatment
Summary
This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methamphetamine | Small molecule | 15 mg | Intravenous |
| Subject | R-(-)-methamphetamine | Unknown | 15 mg | Intravenous |
| Subject | racemic methamphetamine | Unknown | 15 mg | Intravenous |